Stock Analiz

Fulcrum Therapeutics, Inc. FULC

Biotechnology: Pharmaceutical Preparations · IPO 2019 · data as of November 13, 2026

$3.77Market cap $288M
Open the interactive analysis →

Fulcrum Therapeutics, Inc. (FULC) is a healthcare company listed in the US with a market value of about $288M.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -100% a year, a 5-year average ROIC of -27%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 40% below the current price.

About Fulcrum Therapeutics

Fulcrum Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2019. Revenue went from $9M in 2020 to $80M in 2024, growth of about 73.5% a year. It was profitable in 0 of the last 8 years in our data. Its share count rose by 41% over three years (dilution for shareholders).

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B1.0
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-22.7%
Shareholder yield0.0%
Intrinsic value vs. price−40%

Growth and quality

Revenue growth (1 yr)-100.0%
Revenue growth (5 yrs, per year)-100.0%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-1409.1%
ROIC (5-yr avg.)-26.7%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 8 years

Fiscal year20252024202320222021202020192018
Revenue$0$80M$3M$6M$19M$9M——
Net income-$75M-$10M-$97M-$110M-$81M-$71M-$83M-$33M
Free cash flow-$60M-$2M-$91M-$99M-$80M-$55M-$40M-$32M
EPS (diluted)$-1.18$-0.16$-1.59$-2.44$-2.29$-2.79$-8.13$-31.14
Net margin—-12.2%-3470.0%-1732.4%-421.9%-802.7%——
ROIC-18.8%-6.9%-35.5%-41.9%-30.3%-59.4%-76.3%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 3 analysts is $3.67, 3% below the current price; targets range from $3.00 to $4.00; the consensus rating is “Hold”; expected EPS is $-0.84 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Fulcrum Therapeutics stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 40% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Fulcrum Therapeutics pay a dividend?

Not currently.

Is Fulcrum Therapeutics a good stock to buy?

We do not give buy or sell advice. Fulcrum Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.